Find Faculty
Bruce E Sands, MD
img_Bruce E Sands
PROFESSOR | Medicine, Gastroenterology
email
Are you a patient?
View my
Provider Profile
Specialties
Gastroenterology
New topic
Dr. Sands' research as a clinical investigator focuses on extending basic pathogenetic observations in the inflammatory bowel diseases--Crohn's disease and ulcerative colitis--to translational research and clinical trials.  I have been an active investigator in clinical trials of novel agents directed at specific pathophysiologic targets in IBD in all phases of study. His earliest clinical trial work was with infliximab, a chimeric monoclonal anti-tumor necrosis factor antibody that has revolutionized the treatment of Crohn's disease. Dr. Sands was among the first to report on the efficacy of infliximab in ulcerative colitis, later borne out in large randomized controlled trials. Dr. Sands was also overall principal investigator for a large randomized controlled trial of  infliximab in fistulizing Crohn's disease, the largest such study to date.  In addistion to his work in clinical trials, Dr. Sands's research has included extensive work in observational studies in IBD, including outcomes research and epidemiologic studies.  Most recently, he is the principal investigator of OSCCAR, the Ocean State Crohn's & Colitis Area Registry, a novel, prospective, population-based inception cohort of inflammatory bowel disease based in the state of Rhode Island.  The goals of this study are to 1) develope robust predictive models for outcomes in IBD, and 2) to elucidate the role of environmental risk factors in the onset of IBD.

 

 

MD, Boston University School of Medicine

Residency, Internal Medicine, Hospital of the University of Pennsylvania

Fellowship, Gastroenterology, Massachusetts General Hospital

Certifications

American Board of Internal Medicine

2010

Chair, Immunology, Microbiology & Inflammatory Bowel Disease Section

American Gastroenterological Association

2007

Chair, Clinical Research Alliance

Crohn's & Colitis Foundation of America

Fellow

American College of Gastroenterology

Fellow

American Gastroenterological Association

395
Publications

Selected Publications

Longitudinal assessment of sweat-based TNF-alpha in inflammatory bowel disease using a wearable device. Robert P. Hirten, Kai Chun Lin, Jessica Whang, Sarah Shahub, Drew Helmus, Sriram Muthukumar, Bruce E. Sands, Shalini Prasad. Scientific Reports

An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. David T. Rubin, Joana Torres, Iris Dotan, Lan Terry Xu, Irene Modesto, John C. Woolcott, Sean Gardiner, Bruce E. Sands. Inflammatory Bowel Diseases

Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies. Bruce E. Sands, Geert D'Haens, Remo Panaccione, Miguel Regueiro, Subrata Ghosh, David Hudesman, Harris A. Ahmad, Dimpy Mehra, Hsiuanlin Wu, Anjali Jain, Ann Katrin Petersen, Mark T. Osterman, Anita Afzali, Silvio Danese. Clinical Gastroenterology and Hepatology

View All Publications

Annenberg Building Floor 5 Room 12a

1468 Madison Ave

New York, NY 10029

Annenberg Building Floor 5 Room 207cc

1468 Madison Ave

New York, NY 10029

212-241-6744

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sands during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Protagonist Therapeutics, Inc.
  • Boehringer Ingelheim Corporation
  • Target RWE
  • Equilium, Inc.
  • Teva Branded Pharmaceutical Products R&D, Inc.
  • Eli Lilly and Company
  • Adiso Therapeutics USA
  • Synlogic
  • Alimentiv
  • AstraZeneca
  • Takeda Development Center Americas, Inc.
  • Amgen Inc.
  • Cowen Services
  • Galapagos
  • Bristol-Myers Squibb
  • Janssen Pharmaceutica NV
  • Morphic Therapeutic
  • Prometheus Biosciences
  • Immunyx Pharma
  • Kallyope
  • VectivBio AG
  • Takeda Pharmaceuticals International AG
  • Genentech, Inc.
  • Glaxosmithkline
  • Televant
  • WebMD
  • MJH Healthcare Holdings
  • Clinical Care Options, LLC (CCO)
  • Immunic
  • Progenity, Inc.
  • Ferring Pharmaceuticals
  • Vindico Medical Education
  • Aclaris Therapeutics
  • Janssen Research & Development, LLC
  • Celltrion
  • Pfizer Australia Holdings PTY Limited
  • Takeda Distribuidora, Ltd.
  • Agomab Therapeutics
  • Integritas Communications, LLC
  • FirstThought
  • Materia Prima
  • Kyowa Kirin, Inc.
  • Prometheus Laboratories
  • Merck Sharp & Dohme Corp
  • AnaptysBio, Inc
  • Abivax
  • Imhotex
  • AbbVie Inc.
  • MRM Health NV
  • EcoR1 Capital
  • Janssen Research & Development
  • Microbiotica Limited
  • Janssen Biotech, Inc. (formerly Centocor Ortho Biotech Inc.)
  • Alfasigma S.p.A.
  • Ventyx Biosciences
  • Pfizer Inc., U.S. Pharmaceuticals Group

Editorial Services

  • Bristol-Myers Squibb

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Ventyx Biosciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.